Kelly May, MD
Hematology & Oncology · Atlanta, GANPI 1548444045
Payments from drug & device makers
Across 224 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Pfizer$553
- Novartis$260
- Exelixis Inc.$252
- Seagen Inc.$219
- Astellas Pharma US Inc$219
- plus $3K from 35 others
What the payments were for
- Food & beverage$4,34792%
- Education$3828%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $6,758 |
| Pfizer | 35 | $553 |
| Novartis | 12 | $260 |
| Exelixis Inc. | 7 | $252 |
| Seagen Inc. | 11 | $219 |
| Astellas Pharma US Inc | 9 | $219 |
| Johnson & Johnson(2 entities) | 9 | $203 |
| Genentech USA, Inc. | 10 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $176 |
| Bristol Myers Squibb | 7 | $167 |
| Sanofi | 7 | $165 |
| Bayer | 8 | $159 |
| Daiichi Sankyo Inc. | 6 | $149 |
| Eisai Inc. | 6 | $143 |
| Puma Biotechnology, Inc. | 6 | $131 |
| Ipsen Biopharmaceuticals, Inc | 5 | $120 |
| AbbVie | 5 | $111 |
| Beigene USA, Inc. | 5 | $110 |
| GSK | 5 | $108 |
| Sobi, Inc | 5 | $98 |
| Gilead | 5 | $98 |
| Amgen | 4 | $83 |
| Array Biopharma Inc | 7 | $80 |
| Lilly USA, LLC | 3 | $78 |
| Merck | 3 | $63 |
| Servier Pharmaceuticals LLC | 2 | $57 |
| Tersera Therapeutics LLC | 2 | $53 |
| Karyopharm Therapeutics Inc. | 2 | $50 |
| Stemline Therapeutics Inc. | 2 | $49 |
| Incyte Corporation | 2 | $46 |
| Global Blood Therapeutics, Inc. | 2 | $40 |
| Foundation Medicine, Inc. | 2 | $30 |
| Caris MPI, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
How this compares
$11,191 in reported general payments places this provider in the 55th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 62 | $963,239 |
| JakafiRuxolitinib Phosphate | 34 | $493,690 |
| RevlimidLenalidomide | 23 | $487,059 |
| Lenalidomide | 37 | $461,674 |
| BrukinsaZanubrutinib | 24 | $411,339 |
| LenvimaLenvatinib Mesylate | 12 | $299,544 |
| XtandiEnzalutamide | 22 | $288,694 |
| IbrancePalbociclib | 16 | $260,828 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 14 | $88,566 |
| XareltoRivaroxaban | 86 | $82,429 |
| EliquisApixaban | 77 | $55,218 |
| Abiraterone Acetate | 16 | $23,655 |
| Xtampza ErOxycodone Myristate | 11 | $7,543 |
| VeozahFezolinetant | 11 | $5,646 |
| Exemestane | 24 | $5,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $46 | $493,69034 claims |
| Bristol Myers SquibbRevlimid | $167 | $487,05923 claims |
| Beigene USA, Inc.Brukinsa | $110 | $411,33924 claims |
| PfizerIbrance, Panzyga, Eliquis | $553 | $404,612107 claims |
| Eisai Inc.Lenvima | $143 | $299,54412 claims |
| Astellas Pharma US IncXtandi, Veozah | $219 | $294,34133 claims |
| Johnson & JohnsonXarelto | $203 | $82,42986 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $14 | $23,65516 claims |
| Lilly USA, LLCOlanzapine | $78 | $13112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Mehmet BilenAtlanta$21.7M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
- Rodolfo BordoniAtlanta$4M
- Kristie BlumAtlanta$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.